Urteste S.A. launches European multicenter clinical study of the Panuri test

Core Points - Urteste S.A. has launched a European multicenter clinical study for the Panuri test, aimed at detecting pancreatic cancer through urine samples [1][2] - The study will take place in Poland, Hungary, and Italy, with a total of 550 participants [1][5] - The Panuri test has shown promising diagnostic parameters, including 89% sensitivity and 75% specificity [6] Company Overview - Urteste S.A. specializes in innovative technology for early cancer detection, focusing on urine-based diagnostic tests [8] - The company has developed 12 prototypes for various cancers, addressing nearly 70% of global cancer deaths [7] - The technology measures enzyme activity in urine, indicating potential cancer presence through color intensity changes [7][8] Study Details - The primary objective of the study is to evaluate the effectiveness of the Panuri test in detecting pancreatic cancer, focusing on sensitivity and specificity [2] - Two interim analyses will be conducted during the study to assess participant enrollment and diagnostic outcomes [5] - The results will contribute to the certification process for the IVD medical device in Europe and may supplement clinical data for a planned US study [4]